Oncology

Officials with the FDA have granted traditional approval to pembrolizumab (Keytruda; Merck) with trastuzumab- (Herceptin; Genentech), fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥1. Read More ›

Cabozantinib (Cabometyx; Exelixis, Inc) has been approved by the FDA for use in patients aged >12 years who had previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). Read More ›

On March 28, 2025, the FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto; Novartis) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and who are considered appropriate to delay taxane-based chemotherapy. Read More ›

FDA officials recently approved durvalumab (Imfinzi; AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer. Read More ›

Officials with the FDA recently issued a communication in an attempt to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Read More ›

Initial treatment with monoclonal antibodies alone did not boost the risk for other cancers (OCs) in a group of US veterans who had been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), but initial treatment with chemoimmunotherapy was associated with a significant increase of OCs, according to results of a recently presented study. Read More ›

Addressing modifiable risk factors for anticoagulant-related bleeding in patients with cancer is an effective way to reduce bleeding and enable these patients to continue anticoagulant therapy, according to the results of a recently presented study at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

Later cancer treatment initiation and fewer treatment options once treatment starts are just some of the impacts of longer driving distances to treatment, according to researchers reporting in a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

In patients with newly diagnosed multiple myeloma (NDMM), the use of anti-CD38 monoclonal antibodies (mAbs) enhances the effectiveness of standard treatment protocols, according to a study presented at the 66th ASH Annual Meeting & Exposition in San Diego, CA. Read More ›

Zenocutuzumab-zbco (Bizengri; Merus N.V.) has been granted accelerated approval for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy or advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. Read More ›